This ESMO study was conducted under the auspices of the ESMO Global Policy Committee in collaboration with the Cancer Medicines Committee and the National Societies Committee with the following collaborating partners:
Collaborating partners
- Albanian Oncology Association
- Hrvatsko društvo za internističku onkologiju (Croatian Society of Medical Oncology)
- Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO) (German Society of Haematology and Medical Oncology)
- Hellenic Society of Medical Oncology (HeSMO)
- Lietuvos Chemoterapeutᶙ draugija (Lithuanian Society for Medical Oncology)
- Société Luxembourgeoise d'Oncologie (Luxembourg Society of Oncology)
- Polskie Towarzystwo Onkologii Klinicznej, (Polish Society of Clinical Oncology)
- Sociedade Portuguesa de Oncologia, (Portuguese Society of Oncology)
- Russian Society of Clinical Oncology (RUSSCO)
- Udruzenje medikalnih onkologa Srbije (Serbian Society of Medical Oncology)
- Slovenská onkologická spoločnosť (Slovak Oncology Society)
- Sekcija za internistično onklogijo (Slovenian Society for Medical Oncology)
- Sociedad Española de Oncología Médica (SEOM) (Spanish Society of Medical Oncology)
- Svensk Onkologisk Förening (Swedish Society of Oncology)
- Association of Cancer Physicians (ACP)
- Gen&Tiss (External Quality Assessment (EQA))
- French Group of Oncology Cytogenomics (GFCO).